

CRITICAL OUTCOME TECHNOLOGIES ESTABLISHES ADVISORY BOARD FOR THE CLINICAL DEVELOPMENT OF COTI-2

Company also appoints a Clinical Trials Manager

London, Ontario (March 23, 2015): Critical Outcome Technologies Inc. (TSX Venture: COT; OTCQB: COTQF) (“COTI” or the “Company”) announced today the formation of a Scientific Advisory Board (“SAB”) to support the clinical development of its lead cancer drug candidate, COTI-2. Appointed to the Scientific Advisory Board are Dr. Gordon Mills from the University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Douglas Levine from the Memorial Sloan-Kettering Cancer Center in New York City, NY, Dr. David Parkinson from New Enterprise Associates in Menlo Park, CA, and Dr. Marshall Strome from the Center for Head and Neck Oncology at Mount Sinai-Roosevelt Hospital in New York City, NY. The Company also announced that Ashley ten Haaf has joined the Company as its Clinical Trials Manager, responsible for the planning, execution and reporting of clinical trials pursued by the Company.

“We welcome the exceptional quality and depth of clinical and research experience that Doctors Mills, Levine, Parkinson and Strome bring to the new COTI-2 Scientific Advisory Board,” said Dr. Wayne Danter, Chief Executive Officer. “We are also pleased to welcome Ashley ten Haaf to our team as our Clinical Trials Manager. Ashley has a considerable breadth of clinical trial experience in various roles. Together, these individuals bring significant additional resources to our Company and to our COTI-2 clinical development program and our plans related to licensing and partnership opportunities.”

The Company plans to initiate a Phase 1 trial of COTI-2 in patients with gynecological cancers in the summer of 2015 subject to the FDA granting an investigational new drug application for the human trial.

For additional information on these appointments, including bios, please visit our blog at www.criticaloutcomeblog.com/blog-posts.

About Critical Outcome Technologies Inc. (COTI)

COTI is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. COTI’s proprietary artificial intelligence platform, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Critical Outcome Technologies Inc.

Dr. Wayne Danter

President & CEO

Tel: 519-858-5157

Email: wdanter@criticaloutcome.com

Heisler Communications

Trevor Heisler

Investor Relations

Tel: 416-500-8061

Email: trevor@heislercommunications.com

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

Notice to Readers

Information contained in this press release may contain certain statements, which constitute “forward-looking statements” within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statements “... these individuals bring significant additional resources to our Company and to our COTI-2 clinical development program and our plans related to licensing and partnership opportunities” and “... plans to initiate a Phase 1 trial of COTI-2 in patients with gynecologic cancers in the summer of 2015 ...” are forward-looking statements. Forward-looking statements, by their nature, are not guarantees of future performance and are based upon management’s current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.